Market Research Agent - Run Output

Generated: 2026-01-17 14:37:04

User Question

Summarize recent trends in GLP-1 obesity drugs and their market impact.

Planner Agent - Plan

1. Research the latest GLP-1 obesity drugs approved or in development as of 2023-2024.
2. Identify key clinical trial results and efficacy data for these drugs.
3. Analyze market adoption rates and sales figures for GLP-1 obesity drugs.
4. Examine competitive landscape including major pharmaceutical companies involved.
5. Assess the broader market impact including pricing, insurance coverage, and patient demographics.

Planner Agent - Queries

1. recent GLP-1 obesity drugs 2023
2. latest clinical trials GLP-1 weight loss drugs
3. market impact of GLP-1 obesity medications 2024
4. sales figures for GLP-1 weight loss drugs
5. pharmaceutical companies producing GLP-1 obesity drugs
6. trends in obesity treatment drugs 2023-2024
7. insurance coverage for GLP-1 weight loss drugs
8. patient demographics for GLP-1 obesity medications
9. competitive landscape GLP-1 obesity drugs
10. pricing trends GLP-1 weight loss medications

Search Agent - Top Results

What are GLP-3s? Meet the new generation of weight-loss drugs ...

https://www.foxnews.com/health/what-glp-3s-meet-new-generation-weight-loss-drugs-three-key-ingredients

The informal term "GLP-3" refers to a new triple-agonist drug that targets three hormones: GLP-1, GIP (glucose-dependent insulinotropic polypeptide, another naturally occurring hormone released by the gut after eating) and glucagon receptors. The most advanced example is retatrutide by Eli Lilly, according to clinical trial outcomes. OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOU The New England Journal of Medicine published results from a 2023 phase 2 retatrutide trial for obesity, revealing "substantial reductions in body weight" after 48 weeks of treatment. A 12 mg once-weekly injection led to a 24.2% weight reduction, and participants continued to drop pounds after the 48-week trial period. woman stretches her sweatpants out with hands showing belly [...] GLP-1 (glucagon-like peptide-1) medications work by mimicking a naturally occurring hormone in the body that helps regulate blood sugar and appetite. (iStock) Side effects were reportedly similar to GLP-1 medications, most commonly including gastrointestinal complications like nausea, vomiting and diarrhea. Heart rate increases were noted, depending on the dose. ## How it’s different Retatrutide mimics three natural hormones found in the body, compared to GLP-1s that simulate just one hormone, according to a report by GoodRx pharmacists. GIP and GLP-1 hormones signal the pancreas to release insulin after eating, while slowing digestion to help initiate feelings of fullness. NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS — BUT MAY NOT WORK FOR EVERYONE [...] #### US issues new guidance on alcohol consumption GLP-1 drugs can be ‘too easy’ to get online, expert warns #### GLP-1 drugs can be ‘too easy’ to get online, expert warns Dr. Daniel Amen warns about the hidden impact of insufficient sleep on the brain #### Dr. Daniel Amen warns about the hidden impact of insufficient sleep on the brain Retired NASA astronaut says medical evacuation 'under control,' not driven by 'panic' #### Retired NASA astronaut says medical evacuation 'under control,' not driven by 'panic' Hits and Misses of the Week #### Hits and Misses of the Week # What are GLP-3s? Meet the new generation of weight-loss drugs with three key ingredients ## The triple-agonist drug targets three hormones, found to boost weight loss and reduce knee pain in recent trial

WHO Guideline on GLP-1 Therapies for Obesity in Adults

https://jamanetwork.com/journals/jama/fullarticle/2842199

As of October 2025, 12 GLP-1 therapies have been approved for indications in type 2 diabetes and/or obesity, while over 40 agents—including

FDA Approves First Treatment to Reduce Risk of Serious Heart ...

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Therefore, Wegovy should not be used in combination with other semaglutide-containing products or other GLP-1 receptor agonists. [...] “Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight,” said John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research. “This patient population has a higher risk of cardiovascular death, heart attack and stroke. Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health.” Obesity or overweight affect approximately 70% of American adults. Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke. [...] U.S. flag Dot gov The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. SSL The site is secure. The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. U.S. Food and Drug Administration logo ## Featured ## Products ## Topics ## Information For FDA News Release # FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight More Press Announcements Español

What are GLP-3s? Meet the new generation of weight-loss drugs ...

https://www.foxnews.com/health/what-glp-3s-meet-new-generation-weight-loss-drugs-three-key-ingredients

Seven additional phase 3 trials for retatrutide are expected to wrap up in 2026. The drug could see FDA approval in 2027, according to GoodRx.

Weight regain after cessation of medication for weight management

https://www.bmj.com/content/392/bmj-2025-085304

A survey of US adults found that 45% were interested in the use of GLP-1 receptor agonists for weight management, but this proportion declined

2026 is the year of obesity pills from Novo Nordisk, Eli Lilly - CNBC

https://www.cnbc.com/2026/01/10/2026-is-the-year-of-obesity-pills-from-novo-nordisk-eli-lilly-.html

Zepbound has shown average weight loss of more than 20% in late-stage studies. That's higher than results seen with both the Wegovy injection

2024: The obesity market's inflection point? | IQVIA

https://www.iqvia.com/locations/emea/blogs/2024/10/2024-the-obesity-markets-inflection-point

The arrival of the GLP-1 receptor agonists, especially Wegovy, marked an inflection point for the obesity market, because for the first time pharmacological interventions delivered meaningful weight loss of 10-15%. Global obesity spending reached nearly $24bn in 2023, an over sevenfold growth in value in just three years, driven by the advent of new agents, and from 2024 onwards the market is forecasted to accelerate rapidly, with a possible 24-27% CAGR to 2028, and a potential value of up to $131bn by 2028, according to the IQVIA Institute’s Global Use of Medicines 2024 report4. [...] Future competitors will have to clear a high bar to challenge today’s leading two players, possibly delivering weight reduction of 20% or more while demonstrating beneficial cardiovascular outcomes. Recent phase 2 trial readouts from Boehringer Ingelheim/Zealand and Innovent illustrate the battle ahead. Their respective glucagon/GLP-1R dual agonist assets, BI 456906 and mazdutide, delivered weight loss of ~15%, which puts them in the efficacy range of Wegovy, but trailing the 21% weight reduction seen with tirzepatide in a cross-trial comparison, with its inherent caveats. [...] Future competitors will have to clear a high bar to challenge today’s leading two players, possibly delivering weight reduction of 20% or more while demonstrating beneficial cardiovascular outcomes. Recent phase 2 trial readouts from Boehringer Ingelheim/Zealand and Innovent illustrate the battle ahead. Their respective glucagon/GLP-1R dual agonist assets, BI 456906 and mazdutide, delivered weight loss of ~15%, which puts them in the efficacy range of Wegovy, but trailing the 21% weight reduction seen with tirzepatide in a cross-trial comparison, with its inherent caveats.

What is the future of GLP-1 trends - PwC

https://www.pwc.com/us/en/services/consulting/business-model-reinvention/glp-1-trends-and-impact-on-business-models.html

Business Model Reinvention GLP-1 Trends & Impact Survey # From molecules to milestones: Reinventing for the future of weight loss drugs Issue 10 minute read October 2024 ## GLP-1s have revolutionized the treatment of obesity and can compel companies to lead through disruption and reinvent themselves The news has been nearly impossible to miss: A tidal wave of interest in medications that are revolutionizing the approach to weight loss for those with obesity is swiftly evolving. Unlike past diet and weight-loss trends, GLP-1 receptor agonist drugs are generating levels of enthusiasm that have rarely been seen. By increasing insulin production, regulating blood sugar and inducing a sense of fullness, these medications lead to significant weight loss. [...] Some analyst projections show the GLP-1 market reaching $150 billion by 2030. This has been driven by the easing of some manufacturing constraints, improved side effect profiles, new market entrants, increased acceptance by payers, introduction of a simpler-to-take and easier-to-produce oral form, and further penetration into the mainstream. Purpose for taking GLP-1 \Note: Percents do not add up to 100% due to the ability to select multiple options. Q: What is the purpose of taking your GLP-1 medication? Select all that apply. Source: PwC's GLP-1 Trends & Impact Survey, June 2024 base of 2,404. [...] Changes in spending for fitness-related categories while taking GLP-11 Q: While taking your GLP-1 medication, how has your spend in fitness related activities changed? Source: PwC's GLP-1 Trends & Impact Survey, June 2024 base varies. For users motivated to exercise while taking GLP-1, fitness companies could focus on marketing and selling the most demanded workouts (e.g., strength training for rebuilding lean muscle mass). For all GLP-1 users, broader wellness-focused companies could also focus on outstanding areas of health improvement unrelated to being overweight. For example, patients who eat smaller portions may benefit from products that supplement nutritional or energy gaps.

A world on weight loss drugs: How GLP-1s are reshaping the economy

https://www.cnbc.com/2025/08/26/how-glp-1s-wegovy-zepbound-are-reshaping-the-economy.html

Meanwhile in Denmark, Wegovy-maker Novo Nordisk's market capitalization eclipsed that of its home nation's entire GDP in 2024, and the country's large and growing weight loss drug industry continues to have an outsized contribution to the economy. As such, GLP-1s' perceived potential — both in obesity and diabetes treatment as well as other health conditions — is seen sparking a new era of drug innovation, with Dix describing the possible impact as "profound" for both future drug development and new job creation. Pharma giants including AstraZeneca, Pfizer, Roche and Zealand Pharma are already developing competitor obesity treatments, while many more are expanding into metabolic and cardiometabolic disease research, and development with obesity as an entry point. [...] "These consumers which are the most likely to take the drugs are also the ones that are responsible for a lot of consumption," Aljoscha Janssen, assistant professor of economics at the Singapore Management University, said via video call. Unsurprisingly, the most visible impact of that at present is on the food and beverage industry. A 2024 Cornell University study found that households with at least one GLP-1 user cut their grocery spend by 5.3% within six months of adoption, with that rate rising to 8.2% among higher-income households. Penpak Ngamsathain | Moment | Getty Images [...] Goldman Sachs estimates that GLP-1s could boost U.S. gross domestic product (GDP) by 0.4% via increased productivity and healthcare savings, assuming a baseline adoption of 30 million users, according to a 2024 report. An estimated 2% of U.S. adults — approximately 5 million people — were taking GLP-1s as of a May 2025 report from non-profit Fair Health. watch now VIDEO4:1604:16 Novo Nordisk doubles down on direct-to-consumer to boost U.S. Wegovy sales Squawk Box Europe "Poor health imposes significant economic costs that would diminish if health outcomes improve," Goldman Sachs analysts wrote in the report. "Academic studies find that obese individuals are both less likely to work ... and less productive when they do."

GLP-1 Targeted Peptide Weight Loss Drugs Market Size to Reach ...

https://www.novaoneadvisor.com/report/glp-1-targeted-peptide-weight-loss-drugs-market

GLP-1 Targeted Peptide Weight Loss Drugs Market By Drug, 2024-2034 (USD Billion) | | | | | | | | | | | | | --- --- --- --- --- --- | | Year | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | | Semaglutide | 33.65 | 36.38 | 39.28 | 42.34 | 45.57 | 48.95 | 52.48 | 56.15 | 59.93 | 63.79 | 67.70 | | Tirzepatide (Zepbound) | 13.46 | 16.34 | 19.72 | 23.68 | 28.31 | 33.72 | 40.04 | 47.38 | 55.93 | 65.86 | 77.37 | | Liraglutide (Saxenda) | 9.18 | 9.88 | 10.63 | 11.41 | 12.22 | 13.05 | 13.91 | 14.79 | 15.67 | 16.55 | 17.41 | | Others | 4.89 | 6.04 | 7.39 | 8.99 | 10.86 | 13.05 | 15.62 | 18.63 | 22.13 | 26.21 | 30.95 | ## Route of Administration Insights What Made Injectable the Dominant Segment in the Market in 2024? [...] ## Report Scope of GLP-1 Targeted Peptide Weight Loss Drugs Market | | | --- | | Report Coverage | Details | | Market Size in 2025 | USD 68.64 Billion | | Market Size by 2034 | USD 193.44 Billion | | Growth Rate From 2025 to 2034 | CAGR of 12.2% | | Base Year | 2024 | | Forecast Period | 2025-2034 | | Segments Covered | By Drug, By Route of Administration, By Distribution Channel, By Dosage Strength, By End User, By Therapy Line, By Patient Age Group, By BMI Category, By Region | | Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) | | Regional scope | North America; Europe; Asia Pacific; Latin America; MEA | ## Market Dynamics Rising Prevalence of Obesity and Related Metabolic Disorders [...] ## GLP-1 Targeted Peptide Weight Loss Drugs Market By End User, 2024-2034 (USD Billion) | | | | | | | | | | | | | --- --- --- --- --- --- | | Year | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | | Clinics | 18.35 | 21.01 | 24.03 | 27.48 | 31.41 | 35.90 | 41.01 | 46.84 | 53.47 | 61.03 | 69.64 | | Hospitals | 33.65 | 37.07 | 40.82 | 44.94 | 49.45 | 54.39 | 59.81 | 65.74 | 72.22 | 79.31 | 87.05 | | Home Care Facilities | 9.18 | 10.57 | 12.17 | 14.00 | 16.09 | 18.49 | 21.24 | 24.38 | 27.97 | 32.07 | 36.75 | ## Therapy Line

Insights Why is the First Line Segment Dominating the Market in 2024?

Glucagon-Like Peptide-1 Analogues Market to Surpass USD 299.08 ...

https://www.prnewswire.com/news-releases/glucagon-like-peptide-1-analogues-market-to-surpass-usd-299-08-billion-by-2033--fueled-by-the-weight-management-and-diabetes-revolution--datam-intelligence-302596804.html

United States Market The United States dominates the global GLP-1 analogues market, accounting for nearly 65% of global sales, equivalent to USD 40.8 billion in 2024. The U.S. has witnessed explosive adoption due to the unprecedented popularity of weight-loss drugs such as Wegovy and Mounjaro, coupled with favorable reimbursement policies and expanded production capacity by leading pharmaceutical firms. Recent U.S. market developments (2025): Eli Lilly increased production of Mounjaro by 150% with a new USD 2.5 billion manufacturing facility in Indiana. Novo Nordisk announced a USD 4.1 billion expansion plan to enhance Wegovy's global supply and meet U.S. demand. The FDA granted fast-track review status for combination GLP-1/GIP drugs targeting both obesity and metabolic syndrome. [...] Download PDF Brochure: Browse in-depth TOC on 'GLP-1 Analogues Market' 79 – Tables 73 – Figures 215 – Pages Market Segmentation Analysis The global GLP-1 analogues market is segmented By Product, By Type, By Route of Administration, By Application, and By Distribution Channel. By Product The semaglutide-based formulations (marketed under Ozempic, Wegovy, and Rybelsus) dominated the product landscape in 2024, accounting for over 45% of global market share, equivalent to approximately USD 28 billion. These drugs have set new standards for efficacy, with average weight loss of 15–20% observed in clinical trials. [...] Share toX Share this article Share toX AUSTIN, Texas and TOKYO, Oct. 28, 2025 /PRNewswire/ -- According to DataM Intelligence, the Glucagon-like Peptide-1 (GLP-1) Analogues Market is witnessing a transformative expansion, driven by soaring demand for effective obesity management and type 2 diabetes therapies. The GLP-1 Analogues Market Size, valued at USD 62.81 billion in 2024, is projected to reach an astounding USD 299.08 billion by 2033, growing at a CAGR of 17.6% during the forecast period (2025–2033).

GLP-1 Impact: How GLP-1s Are Changing the Diabetes Treatment ...

https://www.iqvia.com/locations/united-states/blogs/2025/11/glp-1-impact-how-glp-1s-are-changing-the-diabetes-treatment-paradigm

Glucagon-like peptide 1 (GLP-1) receptor agonists have taken the healthcare world by storm, becoming one of the most successful drug classes of all time, reaching an astonishing $110 billion in sales in 2024 alone1. Studying how one of the most mature prescription classes in medicine has evolved in just five years provides important strategic lessons for the next generation of healthcare products. What’s driving this meteoric rise? GLP-1s are not just another diabetes medication. Their ability to lower HbA1c levels in Type 2 Diabetes (T2D), combined with impressive weight■loss benefits, has made them a favorite among both doctors and patients, fueling brand and indication conflation while driving rapid growth and popularity. The expansion of GLP-1 utilization has changed the face of T2D [...] " property="og:description"> $110 billion in sales in 2024 alone1. Studying how one of the most mature prescription classes in medicine has evolved in just five years provides important strategic lessons for the next generation of healthcare products. What’s driving this meteoric rise? GLP-1s are not just another diabetes medication. Their ability to lower HbA1c levels in Type 2 Diabetes (T2D), combined with impressive weight■loss benefits, has made them a favorite among both doctors and patients, fueling brand and indication conflation while driving rapid growth and popularity. The expansion of GLP-1 utilization has changed the face of T2D treatment. As more people discover their advantages, GLP-1s are being prescribed earlier in the treatment journey, often displacing longstanding

Six biotech companies that could revolutionize obesity treatments

https://www.labiotech.eu/best-biotech/biotech-companies-revolutionize-obesity-treatments/

The two notable obesity drugs of the company are HRS9531, a dual agonist of GLP-1/GIP and GLP-1 agonist HRS-7535. HRS9531, which has been licensed to American startup Hercules, wowed analysts and investors after a successful phase 2 trial. Patients who took the drug saw a decrease in weight of up to 17% after 24 weeks. The promise of the drug is evidenced by a $400 million investment to Hercules by life science investors for the continued development of the GLP-1/GIP agonist. Jiangsu Hengrui’s oral incretin HRS-7535 is also in the phase 2 stage but patients have not been recruited yet. The study is expected to be completed early next year. [...] Novo Nordisk's obesity drug Wegovy has a major stake in the market having made 9.4 billion Danish kroner ($1.40 billion) in the first quarter of this year, since its approval in 2021. Lilly's dual GIP/GLP-1 receptor agonist injectable Zepbound was greenlit late last year and made over a billion in sales this quarter. [...] Its phase 3 drug survodutide is a GLP-1 receptor dual agonist that works by activating the glucagon and GLP-1 receptors simultaneously that are meant to reduce body weight by both boosting energy burn and reducing food intake. The drug, which has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for metabolic dysfunction-associated steatohepatitis (MASH), has been licensed to German multinational Boehringer Ingelheim for its clinical development to manage obesity. In phase 2 trials, the drug showed up to 19% weight loss in patients after 46 weeks.

Top Leading Anti-Obesity Drug Companies for 2024 - Roots Analysis

https://www.rootsanalysis.com/key-insights/top-anti-obesity-drug-companies.html

AstraZeneca is another pharmaceutical company attempting to bring a weight-loss drug to the marketplace. While the business abandoned its GLP-1 drug candidate, cotadutide, in 2023, it continues pursuing weight-loss medicines. AstraZeneca said last month that it would acquire a license for ECC5004, an anti-obesity medicine, from Eccogene, a Chinese startup. The acquisition might be valued at as much as $2 billion. AstraZeneca claims that the drug they developed may not cause any adverse impact, as there are available injectables in the anti-obesity drug market today. If the clinical outcomes are truthful and promising, it can be a potential weight loss drug in the race to develop obesity treatment. However, the virtual clinical trials results are still in the early stages, and weight loss [...] The drug named Mounjaro®, which is already endorsed for the treatment of Type-2 diabetes, has received approval from the FDA. Furthermore, Novo Nordisk realizes the potential of glucagon-like peptide (GLP-1) drugs that were earlier used as anti-diabetes medicine, which has led their research to tweak their drug formulation and use it for weight loss. The ongoing research of key players in this field will focus on developing cost-effective therapeutic drugs for obesity so people can live healthier and happier lives. Considering the ongoing pace of research, several stakeholders and investors are looking to make considerable investments in the development of anti-obese drugs. In this context, read below the top anti-obesity drug companies currently paving the way for the market to deliver [...] Along with Pfizer, Eli Lilly and Novo Nordisk increased their efforts to develop oral weight loss treatment. The pharmaceutical companies that produce safe and effective oral weight loss pills are considered the leading marketing forces in the long run. This is why investors should consider Pfizer's market potential quickly. 4. AstraZeneca

2026 is the year of obesity pills from Novo Nordisk, Eli Lilly - CNBC

https://www.cnbc.com/2026/01/10/2026-is-the-year-of-obesity-pills-from-novo-nordisk-eli-lilly-.html

Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. A GLP-1 pill from the company's chief rival Eli Lilly isn't far behind, with a U.S. approval expected within months. For some people, pills may serve as a more convenient — and potentially cheaper — alternative to today's blockbuster injections. The cash prices of Novo Nordisk's Wegovy pill range from $149 to $299 per month, depending on the dose, which is slightly less than the newly lowered cash prices of injections. [...] "I think that there are a lot of people out there who have never tried these GLP-1 drugs and are maybe waiting for the pills to come out," said Dr. Eduardo Grunvald, medical director of the UC San Diego Health Center for Advanced Weight Management. "It's kind of a natural preference for some people and even some prescribers." "Secondly, if you have to pay out of pocket, the pills are going to be a bit less expensive than the injections, so that's another reason," he said. The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters [...] Risinger pointed to privately held Verdiva Bio, which is developing several oral peptide treatments designed to be taken once a week. That company has an ongoing phase two trial on an oral GLP-1.

Longitudinal Analysis of Obesity Drug Use and Public Awareness

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829700

. The highest prescription activity was observed for phentermine, semaglutide (Wegovy), tirzepatide (Zepbound), all displaying an upward trend over the study duration (Figure 1A). Notably, by February 2024, phentermine had reached approximately 0.74 million monthly prescriptions. Dispensed prescriptions for Wegovy (approved June 2021) and Zepbound (approved November 2023) reached 0.42 million and 0.25 million monthly prescriptions by February 2024, respectively. Phentermine prescriptions exhibited seasonal peaks each year during the study period, with the highest annual numbers occurring in quarters 2 to 3. Conversely, other OMDs showed a declining trend between July 2017 and February 2024, with monthly prescriptions falling below 0.02 million since October 2023 (Saxenda) or July 2022 [...] . Similarly, tirzepatide showed a clear increase after its initial approval in May 2022 for type 2 diabetes. After receiving the OMD label (Zepbound) in November 2023, tirzepatide prescriptions increased from 1.1 million to 1.4 million monthly prescriptions by February 2024, while liraglutide showed a decline from 0.33 million (July 2017) to 0.11 million (February 2024) monthly prescriptions. Accordingly, online search data were queried for the chemical drug names as depicted in Figure 4B. In line with the corresponding prescription data, the highest overall online search activity was observed for semaglutide, followed by tirzepatide and liraglutide with 705.3, 210.5, and 17.0 searches per 10 million, respectively, in February 2024. [...] ResultsDuring the study period, 69 213 936 prescriptions for OMDs were dispensed in the US, with an overall increase of 0.76 to 0.80 million from July 2017 to June 2018 and 1.29 to 1.51 million from March 2023 to February 2024 and a mean (SD) annual growth rate of 5.3% (9.4%). Total monthly OMD prescriptions reached 1.5 million in February 2024, accounting for 0.41% of all prescriptions that month. Phentermine, semaglutide (Wegovy; Novo Nordisk), liraglutide (Saxenda; Novo Nordisk), and tirzepatide (Zepbound; Eli Lilly) were most prescribed. By February 2024, phentermine had approximately 0.74 million monthly prescriptions, Wegovy had 0.42 million, and Zepbound had 0.25 million. Most prescriptions were issued by advanced practice practitioners (APP) and primary care physicians (PCPs) and

2024: The obesity market's inflection point? | IQVIA

https://www.iqvia.com/locations/emea/blogs/2024/10/2024-the-obesity-markets-inflection-point

The arrival of the GLP-1 receptor agonists, especially Wegovy, marked an inflection point for the obesity market, because for the first time pharmacological interventions delivered meaningful weight loss of 10-15%. Global obesity spending reached nearly $24bn in 2023, an over sevenfold growth in value in just three years, driven by the advent of new agents, and from 2024 onwards the market is forecasted to accelerate rapidly, with a possible 24-27% CAGR to 2028, and a potential value of up to $131bn by 2028, according to the IQVIA Institute’s Global Use of Medicines 2024 report4. [...] ##### The future obesity market: Key drivers Already, 2023 brought a step-change in the treatment paradigm for obesity by introducing highly effective pharmacotherapy options. However, despite increasing prevalence and high unmet need, the extent of their commercial success and the wider outlook for the obesity market are still fraught with uncertainty (Figure 2), and 2024 is the year when the likely commercial path for the obesity market becomes more apparent. Source: IQVIA Forecast Link, IQVIA Institute, Dec 2023 Global Use of Medicines 2024: Outlook to 2028. Report by the IQVIA Institute for Human Data Science. [...] ##### The future obesity market: Key drivers Already, 2023 brought a step-change in the treatment paradigm for obesity by introducing highly effective pharmacotherapy options. However, despite increasing prevalence and high unmet need, the extent of their commercial success and the wider outlook for the obesity market are still fraught with uncertainty (Figure 2), and 2024 is the year when the likely commercial path for the obesity market becomes more apparent. Source: IQVIA Forecast Link, IQVIA Institute, Dec 2023 Global Use of Medicines 2024: Outlook to 2028. Report by the IQVIA Institute for Human Data Science.

Affordable access to GLP-1 obesity medications: strategies to guide ...

https://pmc.ncbi.nlm.nih.gov/articles/PMC12403326/

Throughout 2023 and much of 2024, both semaglutide and tirzepatide were deemed by the FDA to be in shortage due to unprecedented demand. During this time, the high demand for GLP-1 medications created a booming market for compounded versions, especially since many direct-to-consumer telehealth companies and medical spas and clinics have been able to sell compounded versions for a fraction of the price of their name-brand counterparts [25,26]. Many telehealth companies ship compounded GLP-1 drugs after a quick questionnaire, with or without a tele-health clinician visit, with no lab work, lifestyle management, or in-person doctor visit required. One report estimated that as of October 2024 over 2 million Americans had received treatment with compounded versions of GLP-1 drugs . [...] often leading to more than 50% of patients using no medication or less-expensive earlier OMs. For example, the state employee health plan of the state of Connecticut contracts with Flyte for its weight management program. Early results presented in March 2024 showed that 50% of participants were prescribed an OM other than a GLP-1 drug . Patients prescribed non-GLP-1 options lost an average of 5% of baseline weight, and it is unknown what proportion of patients met their weight loss goals. Further evidence is needed on the clinical outcomes of step therapy approaches, but cost savings from helping patients reach weight loss goals without using brand GLP-1s can be significant and is one of the primary ways that weight loss specialty companies are creating savings for purchasers. [...] For commercial plans, coverage decisions are even more varied. One survey of employers by the Pharmaceutical Strategies Group, published in July 2024, found that 33% of health plans and employers were providing coverage for GLP-1 medications for obesity, while an additional 19% of respondents said they were considering coverage . An August 2024 survey from the Business Group on Health, which surveyed 125 large businesses with a total of 17.1 million employees, found that 67% of these larger employers were covering GLP-1s as a treatment for obesity .

Insurance Coverage for GIP and GLP-1 Agonists Like Zepbound ...

https://www.goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds?srsltid=AfmBOooXlp6X9X_Q12jJc0IJ55IZH4iSRMAcfThdI1DCZMTUW92Zi-Py

Save on related medications ozempic mounjaro wegovy zepbound Demand for the GIP and GLP-1 agonists that can cause weight loss has continued to climb in the new year. However, insurance coverage has yet to catch up. The GoodRx Research team is tracking commercial insurance coverage for popular GIP and GLP-1 agonists that have weight-loss benefits, including: Tirzepatide (Zepbound for weight loss, Mounjaro for Type 2 diabetes) Semaglutide (Wegovy for weight loss, Ozempic for Type 2 diabetes) Liraglutide (Saxenda for weight loss, Victoza for Type 2 diabetes) SPECIAL OFFER From GoodRx: Real GLP-1s. Real weight loss results. Weight loss treatment with FDA-approved GLP-1s and same-day pharmacy pickup options, just $39/mo. plus medication costs. Get started SPECIAL OFFER [...] Restrictions continue to limit the vast majority of commercial insurance coverage for GIP and GLP-1 agonists prescribed specifically for weight loss. This means there are restrictions on insurance coverage for Wegovy, Zepbound, and Saxenda for over 88% of people. Even when GIP and GLP-1 agonists are prescribed for Type 2 diabetes, additional restrictions are usually placed on insurance coverage — 78% of the time for Mounjaro and over 81% of the time for Ozempic. Some of the medications that saw coverage changes in 2026 have also seen more restrictions. Compared to 2025, here’s how restrictions have played out: Liraglutide: Since 2025, nearly 8% more people face restrictions on their insurance coverage for generic liraglutide. [...] For those who have coverage for GIP and GLP-1 agonists prescribed for weight loss, over 88% still have to meet additional requirements like prior authorization. And over 16 million people lack commercial insurance coverage for any GIP and GLP-1 agonists prescribed for weight loss.

Employers Grapple With GLP-1 Coverage for Weight Loss - Ogletree

https://ogletree.com/insights-resources/blog-posts/employers-grapple-with-glp-1-coverage-for-weight-loss/

Coverage for GLP-1s for weight loss is not required under the federal Employee Retirement Income Security Act (ERISA). States could add requirements to their insurance laws, meaning that fully insured employers would be required to offer the coverage. About 19 percent of companies with 200 or more workers, and 43 percent of firms with 5,000 or more workers, covered GLP-1 drugs for weight loss in their largest health plan in 2025, according to research from the Peterson Center on Healthcare and the Kaiser Family Foundation (KFF). Using HRAs [...] Next Steps States may pass laws requiring this coverage for insured plans, but for now employers that voluntarily cover GLP-1 drugs may wish to track the number of employees using the benefit and the annual cost. They also may wish to analyze how much obesity, diabetes, and heart disease contribute to their health care costs each year. Along with drug coverage, employers can offer benefits like wellness programs, gym memberships, health coaching, exercise classes, or wearable fitness trackers to encourage employees to maintain a healthy weight. Ogletree Deakins will continue to monitor developments and will provide updates on the Employee Benefits and Executive Compensation and Healthcare blogs as new information becomes available.

Does Medicare Cover Weight-Loss Drugs? Understanding GLP-1 ...

https://www.wellcare.com/en/resources/does-medicare-cover-weight-loss-drugs

Key Takeaways Medicare Part D excludes drugs used only for weight loss. GLP-1s may be covered for FDA-approved uses other than weight loss, such as Type 2 diabetes, cardiovascular risk reduction or obstructive sleep apnea. Coverage varies by plan and depends on the Drug List (formulary) and rules like prior authorization, step therapy and quantity limits. In 2025, Part D caps yearly out-of-pocket costs for covered drugs at $2,000. Coinsurance and deductibles can still apply until you hit the cap. Medicare also covers services that support weight management, including obesity counseling under Part B when you qualify. ## Thinking about Medicare Advantage and GLP-1 Coverage? [...] Wegovy™ (semaglutide) to reduce the risk of cardiovascular death, heart attack or stroke in adults with cardiovascular disease who are overweight or obese. Zepbound™ (trizepatide) for moderate to severe obstructive sleep apnea in adults with obesity. GLP-1s for Type 2 diabetes, such as Ozempic™, Rybelsus™, Trulicity™, Victoza™ and Mounjaro™ when used for blood sugar control. Coverage still depends on your specific plan’s Drug List (also known as a formulary) rules. Coverage decisions are indication-specific. A drug may be covered for one use but not for weight loss. Your plan may have extra rules. If prior authorization is needed, start with your doctor. They will send your plan a request with a letter of medical necessity and medical records that show:

U.S. Obesity Market Analysis: Exploring Demographic & Geographic ...

https://www.realchemistry.com/?p=2774

Sex is another factor. Female patients make up nearly 65% of GLP-1 users nationwide, and around 5.2% of women with obesity are prescribed a GLP-1 medication (compared to 4.2% of men). Women have historically faced greater social pressure to maintain lower body weight—and a recent Pew Research study found that women are more likely to believe willpower alone is insufficient for long-term weight loss, making them potentially more open to medical interventions. ##### GLP-1 Use for Obesity by State Data Source: IRIS by Real Chemistry | Image Credit: Real Chemistry [...] Prior to Wegovy’s FDA approval for obesity, there were approximately 190,000 approved claims for GLP-1 medications to treat obesity each month. By August 2024, that number had risen nearly tenfold to more than 1.8 million monthly approved claims. This data currently includes diabetes-indicated GLP-1s like Ozempic and Mounjaro, given that patients may have dual diagnoses of obesity/type 2 diabetes or some prior obesity diagnosis (during the 10-year analysis period). Over the same period, public interest in these drugs exploded as well, with Google searches for "GLP-1" increasing twentyfold. ##### Demographic Breakdown of GLP-1 Use Data Source: IRIS by Real Chemistry | Image Credit: Real Chemistry [...] GLP-1 users are defined as patients with an approved claim for at least one of the following GLP-1 medications in the prior 12 months: Mounjaro, Ozempic, Rybelsus, Saxenda, Wegovy, and Zepbound. Although Mounjaro, Ozempic, and Rybelsus are not FDA-approved for obesity treatment, they are included in the analysis due to the high number of patients with an obesity diagnosis using these products compared to other FDA-approved diabetes GLP-1 agonists. Patients on Mounjaro, Ozempic, or Rybelsus are only included when they also have an obesity-related diagnosis as described above. Saxenda, Wegovy, and Zepbound patients are included regardless of obesity diagnostic claims.

KFF Health Tracking Poll May 2024: The Public's Use and Views of ...

https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/

While 8% of adults ages 65 and older say they have taken a GLP-1 medication for a chronic condition, just 1% say they have ever taken a GLP-1 drug to lose weight, which may reflect Medicare’s lack of coverage for prescription drugs used for weight loss. Nearly four in ten (37%) adults ages 65 and older report being told by a doctor they are overweight or obese in the past five years. [...] About one in five (19%) adults ages 50-64 say they have ever taken GLP-1 drugs, higher than the shares reported by other age groups. Among adults ages 50-64, 15% say they have taken GLP-1 drugs to treat a chronic condition and 5% say they’ve taken them for weight loss only. Few adults under age 50 report having taken these drugs to treat chronic conditions, but similar shares of 18–29-year-olds (7%) and 30–49-year-olds (6%) report having taken them for weight loss. Among adults ages 65 and over, 8% say they have taken a GLP-1 medication for a chronic condition, while just 1% say they have taken these drugs only to lose weight, which may be a reflection of Medicare’s lack of coverage for prescription drugs used for weight loss. Nearly four in ten (37%) adults ages 65 and older report being

Trends in Newly Filled GLP-1 Receptor Agonist Prescriptions for ...

https://pmc.ncbi.nlm.nih.gov/articles/PMC12636227/

We compared the characteristics of individuals with T2DM and/or obesity and comorbid AUD to those with only T2DM and/or obesity, including age (18–39, 40–49, 50–59, 60–64, 65–69, 70–74, 75–79, 80+ years), insurance category (commercial, Medicare <65 years, Medicare ≥65 years), sex, race and ethnicity (Asian, Black, Hispanic, White, Unknown), use of other on-label medications (acamprosate, disulfiram, and naltrexone) or off-label medications recommended in practice guidelines for specific clinical cirumstances17,18 (gabapentin19 and topiramate)20 or those demonstrating efficacy in treating AUD in clinical trials (varenicline21–23), healthcare utilization (inpatient, outpatient, or emergency department) within 10 days prior to the prescription fill, GLP-1RA-based medication received

Issue 27: Blockbuster GLP-1 Weight-Loss Drugs in Massachusetts

https://masshpc.gov/publications/datapoints-series/issue-27-blockbuster-glp-1-weight-loss-drugs-massachusetts

Future Outlook The landscape for GLP-1 medications will continue to evolve in the coming years. In Massachusetts, more than 1.5 million people have obesity, representing a significant pool of potential patients. Utilization of these drugs will almost certainly increase, as manufacturers ramp up production in response to shortages and seek new indications for approval. Dozens of clinical trials are underway that explore the use of GLP-1 agonists for other conditions, such as liver disease, kidney disease, alcohol use disorders, polycystic ovary syndrome, sleep apnea, and Alzheimer’s.

Market Overview: GLP-1 Agonists and the Obesity Market

https://www.ozmosi.com/market-overview-glp-1-agonists-and-the-obesity-market/

Market Outlook and Strategic Insights The obesity and weight loss treatment landscape will undergo substantial transformation in the coming years. Long-acting injectables may become initial treatments, followed by oral maintenance therapies. This shift could drive the obesity market to exceed $100 billion annually, reducing overall healthcare costs by addressing comorbidities associated with obesity. Despite limited big pharma involvement, venture funding is propelling new companies, potentially reshaping the industry landscape. ##### OZMOSI’s Data Intelligence Platforms: Driving Drug Development Strategies [...] #### ###### ###### Figure 1. BEAM Bulls-eye chart highlighting the R&D landscape for GLP-1 drugs. The closer to the center a drug is, the closer to launch. Oral drugs are designated as orange dots, and blue designates the injectable treatments. ###### ###### Figure 2. Highlighting the eight companies with potential to be acquired in the coming months. #### #### Oral GLP-1 Formulations and Future Projections [...] #### Introduction to GLP-1 Agonists GLP-1 agonists have been pivotal in the pharmaceutical market for nearly two decades, beginning with the FDA approval of AstraZeneca’s Byetta in 2005. Since then, the landscape has seen numerous entries and exits, leaving Novo Nordisk and Eli Lilly as the primary players. These companies currently offer five GLP-1 drugs approved for type 2 diabetes, with four also approved for various cardiovascular conditions. The potential of GLP-1 agonists in weight loss has been a topic of ongoing discussion, but FDA approval for obesity has only been granted in the past decade. ###### ###### Table 1. List of GLP-1 ini6al approvals since 2005 \products no longer on the market #### #### Notable GLP-1 Agonists for Obesity

A look at the R&D landscape in obesity, led by GLP-1s

https://www.fiercebiotech.com/biotech/late-breaking-obesity-glp-1-wegovy-zepbound-novo-lilly-pipeline-rd-landscape

The baselines are already being set. Viking Therapeutics’ dual GLP-1 and GIP agonist produced weight loss of up to 14.7% after 13 weeks of treatment in data released in February. The results were competitive to the Big Pharma heavyweights. While the early-stage pipeline cruises along, Novo and Lilly aren’t wasting any time.

Earlier in March, Wegovy was granted approval to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight. And Lilly showcased data in metabolic dysfunction-associated steatohepatitis (MASH) for tirzepatide. The therapy helped 74% of overweight or obese adults with MASH clear the disease with no worsening of liver scarring, or fibrosis, after 52 weeks. ### Related [...] “Whether these 124 research options are part of that, creating competition and creating a market dynamic that enables payers to feel comfortable to pay for these,” Kleinrock said, “those are questions.” Obesity Novo Nordisk Eli Lilly GLP-1 Wegovy Zepbound semaglutide Ozempic (semaglutide) tirzepatide CRO Research Special Reports Biotech [...] For that reason, he was surprised by the sudden acceleration of phase 1 starts with brand-new, never before seen drugs entering human testing. It’s still early days for most of that phase 1 pipeline, which account for 61 (52%) of the 116 total assets currently in phase 1 through 3 development. Several Big Pharmas are trying their hand in the space, with names like AstraZeneca, Bristol Myers Squibb, Novartis and Amgen touting early-stage assets in obesity. While Novo, and soon to be Lilly, have a tight grip on the market, they will face tough competition in the years to come. What's already clear, though, is that GIP/GLP agonists are the future.

When Will the Cost of GLP-1 Weight Loss Drugs Go Down? - AARP

https://www.aarp.org/health/drugs-supplements/weight-loss-drugs-price-drop/

A new plan to lower the price of GLP-1s The Trump administration announced in early November that it had struck a deal with leading GLP-1 pharmaceutical manufacturers, Eli Lilly and Novo Nordisk, to lower consumer prices for GLP-1 medications. The discounts will apply to purchases made through a new direct-to-consumer platform, TrumpRx, reported to launch in early 2026, as well as through Medicare and Medicaid. [...] GLP-1 medications, however, can help many people lose a significant amount of weight and lower their risks for these other conditions. Studies have found that the drugs can improve heart and liver health and can treat sleep apnea in overweight adults. The medications have also been shown to reduce complications from kidney disease and even protect the brain. Siegel says the current cost of these medications “is definitely a barrier” and that often, patients who could benefit from a GLP-1 are “on other expensive medications” as well. Lowering the cost of GLP-1s for people could have a significant impact on their health. [...] In its announcement, the White House said the cost of Ozempic, Wegovy and Zepbound will fall to roughly $350 a month when purchased through TrumpRx. The medications are all currently injectables, but if an investigational oral GLP-1 called orforglipron is approved by the U.S. Food and Drug Administration (FDA), it will also be about $350 a month, and pending approval, a pill version of Wegovy could cost $150 on the website. Some experts have noted that these prices may vary, depending on the dose. Officials also announced that Medicare prices of Ozempic, Wegovy, Mounjaro and Zepbound will be approximately the same — $245 per month. And copays for Medicare enrollees who use them will be around $50 per month. ### What it means for you

Cheapest GLP-1 Online Programs for 2026 (Ranked and Reviewed)

https://www.vaccinealliance.org/semaglutide/cheapest/

Docimo Jr, S., Shah, J., Warren, G., Ganam, S., Sujka, J., & DuCoin, C. (2024). A cost comparison of GLP-1 receptor agonists and bariatric surgery: What is the break even point? Surgical Endoscopy, 38(11), 6560–6565. Moyad, M. A. (2023). Embracing the pros and cons of the new weight loss medications (semaglutide, tirzepatide, etc.). Current Urology Reports, 24(11), 515–525. [...] #### Medication Costs | Medication | Monthly price | --- | | Ozempic | Insurance only (~$935 if not covered) | | Wegovy | Insurance only (~$1349 if not covered) | | Mounjaro | Insurance only (~$1000 if not covered) | | Zepbound | Cash pay option: ~$349 | | Victoza | Insurance only | | Saxenda | Insurance only | | Compounded meds | Not offered | GLP■1 medications are not included in membership fees. Patients must use insurance for all brand-name medications, except Zepbound, which is available as a direct cash pay option. WeightWatchers does not offer compounded GLP-1 medications. #### Insurance | | | --- | | ■ | Accepts insurance for membership | | ■ | Accepts insurance for prescriptions | | ■ | Offers an insurance concierge | | ■ | Cash payments only | [...] As always, our editorial process prioritizes consistency and accuracy. We aim to eliminate conflicting information and ensure every clinic is described in a trustworthy, transparent manner. Disclaimer:This article is for informational purposes only and should not replace professional medical advice. Always consult your healthcare provider before starting any new treatment. ## Recent Updates November 12, 2025: Updated Shed’s pricing for semaglutide and tirzepatide because they lowered their prices. ## Sources Pearson, S. D., Whaley, C. M., & Emond, S. K. (2025). Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. Journal of Comparative Effectiveness Research, 14(9), e250083.

GLP-1 Agreement: What Group Health Plans Need to Know - Segal

https://www.segalco.com/consulting-insights/glp-1-announcement-may-affect-prices-for-group-health-plans

Because Medicare Part D is currently not permitted to cover GLP-1s for weight loss, it appears that the Centers for Medicare & Medicaid Services (CMS) will create a pilot program to cover the drugs beginning as early as April 2026. According to press reports, the initial pilot program would be voluntary but the program would become mandatory in 2027 — likely through statutory or regulatory action. Part D plans would cover the medications, which would be priced at $245 per month. Copayments for the drugs for Medicare beneficiaries will be no more than $50 per month. The criteria for coverage under Medicare and Medicaid for weight loss was announced to be patients “at high metabolic or cardiovascular risk” with: [...] | Trulicity® (dulaglutide) injectable | This drug will be added to LillyDirect and made available with pricing 50-60% off current list prices. It could be $389 per month. | Eli Lilly | | Wegovy® (semaglutide) injectable | Lowest dose at $350 | Novo Nordisk | | Wegovy pill awaiting FDA approval | Lowest dose at $150 | Novo Nordisk | | Zepbound® (tirzepatide) multi-dose pen | Lowest dose at $299, with additional doses up to $449 | Eli Lilly |

Retriever Agent - Extracted Evidence Bullets

1. GLP-3 drugs are a new triple-agonist class targeting GLP-1, GIP, and glucagon receptors, with retatrutide by Eli Lilly showing a 24.2% weight reduction after 48 weeks in a 2023 phase 2 trial (Fox News, 2023).

2. As of October 2025, 12 GLP-1 therapies have been approved for type 2 diabetes and/or obesity, with over 40 agents in development (JAMA, 2025).

3. Wegovy (semaglutide) is the first weight loss medication approved to reduce cardiovascular risk in adults with obesity or overweight and cardiovascular disease (FDA, 2023).

4. Seven additional phase 3 trials for retatrutide are expected to complete by 2026, with potential FDA approval in 2027 (Fox News, 2023).

5. Zepbound (tirzepatide) has shown average weight loss of over 20% in late-stage studies, outperforming Wegovy injections (CNBC, 2026).

6. Global obesity spending reached nearly $24 billion in 2023, with a forecasted CAGR of 24-27% to 2028, potentially reaching $131 billion (IQVIA, 2024).

7. GLP-1 drugs have revolutionized obesity treatment by delivering meaningful weight loss of 10-15%, with future competitors aiming for 20%+ weight loss and cardiovascular benefits (IQVIA, 2024).

8. PwC projects the GLP-1 market could reach $150 billion by 2030, driven by manufacturing improvements, new entrants, oral formulations, and payer acceptance (PwC, 2024).

9. Novo Nordisk's market cap surpassed Denmark's GDP in 2024 due to GLP-1 drug sales, with GLP-1s expected to boost US GDP by 0.4% through productivity and healthcare savings (CNBC, 2025).

10. The GLP-1 targeted peptide weight loss drugs market is projected to grow from $68.64 billion in 2025 to $193.44 billion by 2034, at a CAGR of 12.2% (NovaOneAdvisor, 2024).

11. The US dominates the GLP-1 analogues market with 65% of global sales, about $40.8 billion in 2024, led by semaglutide-based drugs (PR Newswire, 2025).

12. GLP-1 receptor agonists reached $110 billion in sales in 2024, driven by their dual benefits for type 2 diabetes and weight loss (IQVIA, 2025).

13. Hercules received $400 million investment for HRS9531, a dual GLP-1/GIP agonist showing 17% weight loss in phase 2 trials (Labiotech, 2024).

14. Novo Nordisk's Wegovy made $1.4 billion in Q1 2024; Eli Lilly's Zepbound made over $1 billion in the same quarter (Labiotech, 2024).

15. Novo Nordisk and Eli Lilly are developing oral GLP-1 pills, with Novo's Wegovy pill priced $149-$299/month and Eli Lilly's approval expected soon (CNBC, 2026).

16. By February 2024, monthly prescriptions in the US were approximately 0.74 million for phentermine, 0.42 million for Wegovy, and 0.25 million for Zepbound (JAMA Network Open, 2024).

17. Most GLP-1 prescriptions are issued by advanced practice practitioners and primary care physicians (JAMA Network Open, 2024).

18. Women constitute about 65% of GLP-1 users in the US, with 5.2% of women with obesity prescribed GLP-1s versus 4.2% of men (Real Chemistry, 2024).

19. Google searches for 'GLP-1' increased twentyfold by August 2024, reflecting rising public interest (Real Chemistry, 2024).

20. About 19% of companies with 200+ employees and 43% with 5,000+ employees covered GLP-1 drugs for weight loss in 2025 (Ogletree, 2025).

21. Medicare Part D excludes coverage for GLP-1 drugs used solely for weight loss but may cover them for diabetes or cardiovascular indications; pilot coverage programs may start in 2026 (Wellcare, 2025; Segal, 2025).

22. Insurance coverage for GLP-1 weight loss drugs remains limited, with over 88% of people facing restrictions like prior authorization (GoodRx, 2026).

23. The Trump administration announced a deal to lower GLP-1 drug prices to about $350/month via a direct-to-consumer platform launching in 2026, with Medicare copays around $50/month (AARP, 2025).

24. Novo Nordisk plans a $4.1 billion expansion to increase Wegovy supply; Eli Lilly increased Mounjaro production by 150% with a $2.5 billion facility (PR Newswire, 2025).

25. GLP-1 drugs are being studied for additional indications including liver disease, kidney disease, alcohol use disorders, sleep apnea, and Alzheimer's (Massachusetts HPC, 2024).

26. The obesity market is expected to exceed $100 billion annually, driven by long-acting injectables and oral maintenance therapies (Ozmosi, 2024).

27. Novo Nordisk and Eli Lilly dominate the GLP-1 obesity drug market but face competition from companies like AstraZeneca, Bristol Myers Squibb, and others developing early-stage obesity treatments (Fierce Biotech, 2024).

28. GLP-1 drugs improve heart and liver health, treat sleep apnea, reduce kidney disease complications, and protect the brain, beyond weight loss (AARP, 2025).

29. GLP-1 medications are often expensive, creating barriers to access; lowering costs could significantly improve patient health outcomes (AARP, 2025).

30. The GLP-1 market includes injectable and oral formulations, with oral drugs expected to increase market penetration (Ozmosi, 2024).

31. Pharmaceutical companies are investing heavily in GLP-1 and dual agonist drugs, with multiple phase 2 and 3 trials ongoing (Fox News, 2023; Labiotech, 2024).

Synthesizer Agent - Draft Report

The GLP-1 drug market has experienced rapid growth and innovation, fundamentally transforming obesity and type 2 diabetes treatment. As of 2025, twelve GLP-1 therapies have been approved, with over 40 agents in development, reflecting robust pharmaceutical investment and clinical interest. These drugs deliver significant weight loss benefits, typically in the 10-15% range, with newer agents like Eli Lilly's retatrutide and tirzepatide (Zepbound) demonstrating even greater efficacy, achieving weight reductions exceeding 20% in clinical trials. Retatrutide, a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showed a 24.2% weight reduction after 48 weeks in a 2023 phase 2 trial, with multiple phase 3 trials underway and potential FDA approval anticipated by 2027.

The market dynamics are underscored by substantial financial growth. Global obesity-related spending reached nearly $24 billion in 2023 and is forecasted to grow at a compound annual growth rate (CAGR) of 24-27% through 2028, potentially reaching $131 billion. The GLP-1 targeted peptide weight loss drug market alone is projected to expand from $68.64 billion in 2025 to $193.44 billion by 2034, at a CAGR of 12.2%. PwC projects the GLP-1 market could reach $150 billion by 2030, driven by manufacturing improvements, new market entrants, oral formulations, and increasing payer acceptance. Notably, Novo Nordisk's market capitalization surpassed Denmark's GDP in 2024, fueled by GLP-1 drug sales, and these therapies are expected to contribute positively to the US GDP through enhanced productivity and healthcare savings.

The United States dominates the GLP-1 analogues market, accounting for 65% of global sales, approximately $40.8 billion in 2024, led by semaglutide-based drugs such as Wegovy. Wegovy is notable as the first weight loss medication approved to reduce cardiovascular risk in adults with obesity or overweight and cardiovascular disease. In Q1 2024, Novo Nordisk's Wegovy generated $1.4 billion in sales, while Eli Lilly's Zepbound achieved over $1 billion, highlighting strong market demand. Monthly prescriptions in the US reflect this trend, with approximately 0.42 million for Wegovy and 0.25 million for Zepbound as of early 2024. Women constitute about 65% of GLP-1 users, with a higher prescription rate among women with obesity compared to men.

Despite the clinical and commercial success, access challenges remain. Insurance coverage for GLP-1 weight loss drugs is limited, with over 88% of patients facing restrictions such as prior authorization. Medicare Part D excludes coverage for GLP-1 drugs used solely for weight loss but may cover them for diabetes or cardiovascular indications, with pilot coverage programs expected to begin in 2026. To address affordability, the Trump administration announced a deal to lower GLP-1 drug prices to approximately $350 per month via a direct-to-consumer platform launching in 2026, with Medicare copays around $50 per month.

Pharmaceutical companies are expanding production capacity to meet growing demand. Novo Nordisk plans a $4.1 billion expansion to increase Wegovy supply, while Eli Lilly has increased Mounjaro production by 150% with a $2.5 billion facility. Both companies are also developing oral GLP-1 formulations, with Novo Nordisk's Wegovy pill priced between $149 and $299 per month and Eli Lilly's oral GLP-1 approval anticipated soon, which is expected to enhance market penetration and patient adherence.

Beyond weight loss, GLP-1 drugs offer additional health benefits, including improvements in heart and liver health, treatment of sleep apnea, reduction of kidney disease complications, and neuroprotection. Ongoing research is exploring their potential in liver disease, kidney disease, alcohol use disorders, sleep apnea, and Alzheimer's disease.

The competitive landscape includes dominant players Novo Nordisk and Eli Lilly, alongside emerging competitors such as AstraZeneca and Bristol Myers Squibb, who are developing early-stage obesity treatments. The market is expected to exceed $100 billion annually, driven by long-acting injectables and oral maintenance therapies.

In summary, GLP-1 drugs represent a transformative advancement in obesity and diabetes care, with strong clinical efficacy, expanding market size, and evolving access frameworks. Continued innovation, increased affordability, and broader insurance coverage will be critical to maximizing patient health outcomes and sustaining market growth.

Validator Agent - Validation Output

1. VALID: The GLP-1 drug market has experienced rapid growth and innovation, fundamentally transforming obesity and type 2 diabetes treatment.

2. VALID: As of 2025, twelve GLP-1 therapies have been approved, with over 40 agents in development.

3. VALID: GLP-1 drugs deliver significant weight loss benefits, typically in the 10-15% range.

4. VALID: Newer agents like Eli Lilly's retatrutide and tirzepatide (Zepbound) demonstrate weight reductions exceeding 20% in clinical trials.

5. VALID: Retatrutide showed a 24.2% weight reduction after 48 weeks in a 2023 phase 2 trial, with multiple phase 3 trials underway and potential FDA approval anticipated by 2027.

6. VALID: Global obesity-related spending reached nearly $24 billion in 2023 and is forecasted to grow at a CAGR of 24-27% through 2028, potentially reaching $131 billion.

7. VALID: The GLP-1 targeted peptide weight loss drug market is projected to expand from $68.64 billion in 2025 to $193.44 billion by 2034, at a CAGR of 12.2%.

8. VALID: PwC projects the GLP-1 market could reach $150 billion by 2030, driven by manufacturing improvements, new market entrants, oral formulations, and increasing payer acceptance.

9. VALID: Novo Nordisk's market capitalization surpassed Denmark's GDP in 2024, fueled by GLP-1 drug sales, and these therapies are expected to contribute positively to the US GDP.

10. VALID: The United States dominates the GLP-1 analogues market, accounting for 65% of global sales, approximately $40.8 billion in 2024, led by semaglutide-based drugs such as Wegovy.

11. VALID: Wegovy is the first weight loss medication approved to reduce cardiovascular risk in adults with obesity or overweight and cardiovascular disease.

12. VALID: In Q1 2024, Novo Nordisk's Wegovy generated $1.4 billion in sales, while Eli Lilly's Zepbound achieved over $1 billion.

13. VALID: Monthly prescriptions in the US were approximately 0.42 million for Wegovy and 0.25 million for Zepbound as of early 2024.

14. VALID: Women constitute about 65% of GLP-1 users, with a higher prescription rate among women with obesity compared to men.

15. VALID: Insurance coverage for GLP-1 weight loss drugs is limited, with over 88% of patients facing restrictions such as prior authorization.

16. VALID: Medicare Part D excludes coverage for GLP-1 drugs used solely for weight loss but may cover them for diabetes or cardiovascular indications, with pilot coverage programs expected to begin in 2026.

17. VALID: The Trump administration announced a deal to lower GLP-1 drug prices to approximately $350 per month via a direct-to-consumer platform launching in 2026, with Medicare copays around $50 per month.

18. VALID: Novo Nordisk plans a $4.1 billion expansion to increase Wegovy supply, while Eli Lilly has increased Mounjaro production by 150% with a $2.5 billion facility.

19. VALID: Both companies are developing oral GLP-1 formulations, with Novo Nordisk's Wegovy pill priced between $149 and $299 per month and Eli Lilly's oral GLP-1 approval anticipated soon.

20. VALID: GLP-1 drugs offer additional health benefits, including improvements in heart and liver health, treatment of sleep apnea, reduction of kidney disease complications, and neuroprotection.

21. VALID: Ongoing research is exploring GLP-1 drugs' potential in liver disease, kidney disease, alcohol use disorders, sleep apnea, and Alzheimer's disease.

22. VALID: The competitive landscape includes dominant players Novo Nordisk and Eli Lilly, alongside emerging competitors such as AstraZeneca and Bristol Myers Squibb developing early-stage obesity treatments.

23. VALID: The obesity market is expected to exceed $100 billion annually, driven by long-acting injectables and oral maintenance therapies.

24. VALID: GLP-1 drugs represent a transformative advancement in obesity and diabetes care, with strong clinical efficacy, expanding market size, and evolving access frameworks.